Hervycta 440 + Injection contains Trastuzumab 440 mg, a recombinant humanized monoclonal antibody targeting the HER2 receptor, indicated for the treatment of HER2-positive breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumab binds specifically to the extracellular domain of the HER2 receptor, inhibiting proliferation of tumor cells that overexpress HER2, thereby mediating antibody-dependent cellular cytotoxicity. Hervycta 440 + Injection is administered intravenously under the supervision of a qualified healthcare professional, with dosing tailored according to patient weight and clinical response. It is used as monotherapy or in combination with chemotherapy agents such as paclitaxel or docetaxel. Prior to initiation, patients should be evaluated for cardiac function due to potential cardiotoxicity associated with Trastuzumab. Common adverse reactions include infusion-related reactions, fever, chills, nausea, and fatigue. Monitoring during treatment is essential to detect any signs of cardiotoxicity or hypersensitivity. Hervycta 440 + Injection should be stored under recommended conditions and handled with care to maintain stability and efficacy. This therapeutic agent represents a significant advancement in targeted cancer therapy, improving clinical outcomes in patients with HER2-positive malignancies.